AVDL

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is an Irish biopharmaceutical company that has transformed from a generic drug manufacturer into a specialized narcolepsy treatment company. Originally founded as Flamel Technologies SA in France in 1990, the company rebranded to Avadel Pharmaceuticals in 2017 following strategic acquisitions and restructuring. The company went public in 1996 and is now headquartered in Dublin, Ireland, with operations focused on the United States market. Avadel has successfully commercialized its lead product LUMRYZ, a once-nightly treatment for narcolepsy, and is expanding into adjacent sleep disorder markets.